*By Carlo Versano* The shocking rise in teen vaping is a public health crisis that the FDA has been slow to address, according to a nationally recognized cardiologist. Dr. Kevin Campbell, who is also CEO of Pace Mate, a digital cardiac monitoring service, said the [recent study](https://www.cnbc.com/2019/02/11/e-cigarettes-single-handedly-drives-spike-in-teen-tobacco-use-cdc.html) from the CDC that linked vaping to a spike in teen tobacco use shows that more serious steps need to be take. The first step? Get rid of the flavored nicotine "pods," which Campbell said are acting as a gateway for teenage beginner vapers to get hooked on nicotine. "We don't know the long-term health effects yet," Campbell said. "I can't emphasize that enough." While popular vape products are unarguably "healthier" than combustible cigarettes, they still involve the delivery of an addictive drug (nicotine), that is known to do damage to the heart and blood vessels. And there is not enough data on the additives and preservatives that go into the pods. "They may be doing deleterious things to our bodies as well," Campbell said. One in five American high schoolers now vapes, according to the CDC, which is enough to cause alarm at the FDA. That agency recently announced a crackdown on vaping companies that market to teens, but that's not enough, in Campbell's opinion. "I think the FDA is a little bit late to the show here," he said. It's going to require a national education program ー think D.A.R.E. for a new era ー that explains the unknowns and risks involved in vaping. "We need to get ahead of it," Campbell said. For full interview [click here](https://cheddar.com/videos/teen-tobacco-product-use-on-the-rise).

Share:
More In Business
Regeneron Joins Battle Against COVID-19, Releases Stats on New COVID Treatment
The world hit a grim milestone on Monday, with COVID-19 cases surpassing a quarter of a billion worldwide. As cases increase, the fight to beat the virus continues as well, with a number of medical breakthroughs coming out over the last few months in the form of pills from Pfizer and Merck. Regeneron is now the latest company to join the fight, recently releasing new data on a covid antibody cocktail. Professor Peter Pitts, former FDA Associate Commissioner and the founder of the Center for Medicine in the Public Interest breaks down the differences between the 3 treatments and why vaccines are still among the fire line of defense.
Peloton Stock Continues Steep Drop as It Loses More Than $10B in Value
Doug Astrop, managing partner at Exponential Investment Partners, joined Cheddar to discuss Peloton's precipitous price drop, and whether the company can recover as the at-home workout trend tapers off. "They've lowered the prices on their equipment to try to attract a bigger audience because ultimately they're sort of headed to this Apple ecosystem model where they can monetize a loyal customer base," he said. Astrop noted that he believes there is a reality where the in-person gym experience and Peloton's at-home programs can co-exist.
Markets Look to Continue Record Run
Bill Stone, Chief Investment Officer at Glenview Trust Company, joined Wake Up With Cheddar to break down markets headlines ahead of the start of the trading week.
Load More